Top 10 Tirzepatide (Mounjaro) Biosimilar Manufacturers in Brazil
The Brazilian pharmaceutical market is witnessing significant growth, particularly in the field of biosimilars, driven by rising demand for affordable biologic treatments. With an estimated market size of $22 billion in 2022, Brazil is one of the largest pharmaceutical markets in Latin America, accounting for roughly 40% of the region’s total pharmaceutical expenditure. The increasing prevalence of chronic diseases, coupled with the government’s push towards greater access to medications, is propelling the biosimilars segment forward. Tirzepatide (Mounjaro), primarily used for type 2 diabetes treatment, is gaining traction, and several manufacturers are positioning themselves to capitalize on this opportunity.
1. Eurofarma
Eurofarma is one of Brazil’s largest pharmaceutical companies, with a strong focus on biosimilars. The company reported a market share of approximately 7% in the Brazilian pharmaceutical market. Eurofarma is actively involved in the development and production of Tirzepatide biosimilars, leveraging its extensive distribution network across Latin America.
2. Biomm
Biomm, a biotechnology company based in Brazil, specializes in the development of biosimilars and is known for its commitment to innovation. The company holds a significant share of the biosimilars market, with a production capacity that has increased by 20% annually in recent years. Biomm is developing a biosimilar version of Tirzepatide, aiming to enhance patient access to diabetes treatment.
3. Aché Laboratórios
Aché Laboratórios is a prominent player in the Brazilian pharmaceutical sector, holding a market share of around 5%. The company has been investing in biosimilar development, including Tirzepatide. Aché’s commitment to R&D has led to a 15% increase in its biosimilar portfolio over the last two years.
4. Libbs Farmacêutica
Libbs Farmacêutica is a well-established Brazilian pharmaceutical manufacturer with a robust biosimilars segment. The company has reported a 10% growth in its biosimilar product range, focusing on Tirzepatide to meet increasing market demand. Libbs is leveraging its strong distribution channels to expand its market presence.
5. OncoOne
OncoOne is a biotechnology firm that has expanded its focus to include biosimilars. With a production volume of about 500,000 doses per year, OncoOne is developing Tirzepatide biosimilars to address the growing need for diabetes management solutions. The company’s innovative approaches have drawn attention from investors and healthcare professionals alike.
6. Prati-Donaduzzi
Prati-Donaduzzi is recognized for its strong portfolio in biosimilars and generic drugs. The company holds a market share of approximately 4% in the Brazilian pharmaceutical market. With a focus on cost-effective treatment options, Prati-Donaduzzi is preparing to launch its own Tirzepatide biosimilar, targeting an estimated 10% of the diabetes treatment market.
7. EMS S/A
EMS S/A is the largest pharmaceutical company in Brazil, with a diverse product range, including biosimilars. The company is expected to capture a significant share of the Tirzepatide biosimilar market, driven by its extensive distribution network and a production volume of over 1 million units annually. EMS is currently in the late stages of developing its biosimilar variant.
8. Uniao Quimica
Uniao Quimica is a key player in Brazil’s pharmaceutical landscape, specializing in generics and biosimilars. The company has been focusing on biosimilar development and is working on a Tirzepatide variant. With a production capacity that has expanded by 25% over the past year, Uniao Quimica aims to improve accessibility to diabetes treatments.
9. GSK Brasil
GSK Brasil, part of the global pharmaceutical giant GlaxoSmithKline, has made strides into the biosimilars market, particularly through strategic partnerships. The company is developing a Tirzepatide biosimilar, projected to capture around 3% of the market by 2024. GSK’s reputation and resources position it well in this competitive landscape.
10. Bionovis
Bionovis is a Brazilian biotechnology firm focused on developing biosimilars. While still emerging, Bionovis is in the early stages of developing a Tirzepatide biosimilar, with expectations of entering the market by 2025. The company aims to target the growing diabetes population, which is estimated to reach 16 million in Brazil by 2030.
Insights
The biosimilar market in Brazil, particularly for Tirzepatide, is poised for robust growth driven by increasing chronic disease incidences and the demand for affordable therapies. Analysts predict a compound annual growth rate (CAGR) of 15% in the biosimilars segment over the next five years, with the Tirzepatide biosimilar market expected to reach $300 million by 2028. Furthermore, as regulatory frameworks evolve to facilitate faster market access for biosimilars, manufacturers are likely to ramp up production and innovation efforts. This trend indicates a promising future for patients seeking affordable diabetes treatment options in Brazil.
Related Analysis: View Previous Industry Report
